P.248 Anti-CD19 CAR T cell therapy in systemic sclerosis - update on seven patients from tuebingen

Introduction Systemic sclerosis (SSc) is associated with a high morbidity and mortality (1, 2). Immunosuppressive and cellular therapies such as autologous stem cell transplantation (HSCT) are used (3). Chimeric antigen receptor (CAR) T cell therapy is a promising alternative option (4-8). Here we report an update on our experiences with CD19-targeting CAR T cells in a cohort of 7 patients with SS…